A Phase I First-in-Human Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of AZD8701 Administered Intravenously as Monotherapy and in Combination With Durvaluamb (MEDI4736) in Participants With Advanced Solid Tumours.
The purpose of this study is to Evaluate the Safety, Tolerability, Pharmacokinetics,
Pharmacodynamics, Immunogenicity and Antitumor Activity of AZD8701 Alone and in Combination
with Durvalumab (MEDI4736) in Adult Subjects with Select Advanced Solid Tumors
This is a Phase I, First in Human, multicentre, open-label, multiple arm study with dose
escalations and expansions at selected doses. Dose-escalation will occur with AZD8701 in
monotherapy (Part 1) and in combination with durvalumab (Part 3) in selected participants
with HNSCC, TNBC, NSCLC, ccRCC, gastroesophageal cancer, melanoma, cervical cancer,
small-cell lung cancer and/or participants with solid tumours who have demonstrated a
response to prior PD-(L)1 treatment.
Disease specific expansions will occur with a selected dose of AZD8701 in participants with
NSCLC (Part 2) and with a selected dose of AZD8701 and durvalumab in participants with TNBC
and clear cell RCC (Part 4).
Clear Cell Renal Cell Cancer, Non-Small-Cell Lung Cancer, Triple Negative Breast Neoplasms, Squamous Cell Cancer of Head and Neck, Small Cell Lung Cancer, Gastroesophageal Cancer, Melanoma, Cervical Cancer, Advanced Solid Tumours
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.